Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The company exports mobile surgery equipment to over 100 countries from Pune
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Cipla has reported consolidated financial results for the period ended March 31, 2022
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The partners also aim to expand their work to Latin America for the first time
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Subscribe To Our Newsletter & Stay Updated
